Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Treated With Clozapine and Olanzapine And Potential Effects on Cognitive Function.

Trial Profile

Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Treated With Clozapine and Olanzapine And Potential Effects on Cognitive Function.

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Dyslipidaemias; Glucose intolerance
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Apr 2010 Actual end date added as Jan 2010 as reported by clinicaltrials.gov.
    • 27 Apr 2010 Status changed from recruiting to completed as reported by clinicaltrials.gov.
    • 23 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top